NCT06893757 Prospective Cohort of People Starting Treatment for Tuberculosis Disease in France (FrenchTB)
| NCT ID | NCT06893757 |
| Status | Recruiting |
| Phase | — |
| Sponsor | ANRS, Emerging Infectious Diseases |
| Condition | Tuberculosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2026-05-06 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2026-05-06 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The French Tuberculosis Cohort is a prospective, national, multicenter, low-intervention study including subjects aged 18 years and older with tuberculosis disease for which inpatient treatment is initiated. The goal of this observational study is to follow-up and anti-tuberculosis treatment will be provided according to current French recommendations. Participants will provide sociodemographic, clinical, biological, radiological and bacteriological data at various protocol visits at 2 days, 1 and 2 weeks, 2 months, at the end of treatment, 12 and 24 months. Consenting participants will have samples collected at scheduled visits for the establishment of a biobank. This will include blood, urine, breath and hair samples. The positive mycobacterial strains will constitute a specimen bank.
Eligibility Criteria
Inclusion Criteria: * Aged ≥18 years. * Diagnosis of tuberculosis by microbiological or clinical means, including on the basis of a pathological examination for extrapulmonary tuberculosis leading to a Compulsory Declaration (CD) and treated for less than 8 days. * Have signed a voluntary, informed and written consent (at the latest on the day of inclusion and before any examination carried out as part of the research), or alternatively, consent from relatives in cases of tuberculous meningitis or other serious forms of tuberculosis with impaired consciousness or confusion, until the person is able to give their consent. Exclusion Criteria: * Presence of significant cognitive impairment that, in the opinion of the site investigator or designated person, may affect the ability to give reliable informed consent (except in the specific case of meningeal tuberculosis).
Contact & Investigator
Nathalie DE CASTRO, MD PHD
PRINCIPAL INVESTIGATOR
Hôpital Saint Louis Paris
Frequently Asked Questions
Who can join the NCT06893757 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Tuberculosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06893757 currently recruiting?
Yes, NCT06893757 is actively recruiting participants. Contact the research team at olivier.marcy@u-bordeaux.fr for enrollment information.
Where is the NCT06893757 trial being conducted?
This trial is being conducted at Paris, France, Saint-Denis, France.
Who is sponsoring the NCT06893757 clinical trial?
NCT06893757 is sponsored by ANRS, Emerging Infectious Diseases. The principal investigator is Nathalie DE CASTRO, MD PHD at Hôpital Saint Louis Paris. The trial plans to enroll 2,000 participants.